We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




某些类型肺癌可见致癌基因融合

By LabMedica International staff writers
Posted on 26 Nov 2013
Print article
肺腺癌(非小细胞肺癌的一种形式)的某些子集由产生致癌的“融合基因”的突变所引发。

美国达纳-法伯癌症研究所 (Boston, MA, USA)和科罗拉多大学癌症中心 (Denver, USA)的研究者们对 36 名肺腺癌患者的肿瘤样品进行了下一代 DNA 测序,这些肿瘤患者没有任何已知的致癌基因突变。研究者发现,取自两位不吸烟女性患者样品的 NTRK1(神经营养性酪氨酸激酶受体 1 型)区域已融合为常见的远端基因(1 位患者发生于 MPRIP 基因,1 位患者发生于 CD74 基因)。

结果发表于 2013 年 10 月 27 日网络版的 Nature Medicine 杂志,揭示三份样品 (3.3%) 显示出 NTRK1 基因融合证据。

“这些结果提示,少数百分比的肺腺癌患者——此前没能发现癌细胞基因异常的人群——肿瘤生长受涉及 NTRK1 融合的驱动,”特约作者,达纳-法伯癌症研究所医学副教授 Pasi A. Jänne 博士声称。“由于肺癌是一种常见的癌症,即使是百分之几的比率也具有显著的意义,经换算可成为大量的患者数量。我们的研究结果表明,针对此子集的肺癌患者进行靶向治疗可能有效。”

Related Links:
达纳-法伯癌症研究所 
科罗拉多大学癌症中心

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.